Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2023 Filed May 12, 2023 22:56 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 5,869 | $5.93 | $34,780.28 |
DisclosureSEC source: 0001376339-23-000028 · wf-form4_168393215769457.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,775 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| May 10, 2023 Filed May 12, 2023 22:50 UTC |
Carlson Peter MChief Financial Officer
|
SaleCommon Stock | 5,976 | $5.93 | $35,414.37 |
DisclosureSEC source: 0001376339-23-000024 · wf-form4_168393180333729.xml · nonDerivative · entry 1 Carlson Peter M · CIK 0001379320 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,435 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| May 04, 2023 Filed May 9, 2023 12:32 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 51,756 | $5.34 | $276,470.20 |
DisclosureSEC source: 0001376339-23-000022 · wf-form4_168363556235229.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,644 F1 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $5.125 to $5.540, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 02, 2023 Filed May 3, 2023 22:26 UTC |
Phelan William LawrenceChief Accounting Officer
|
SaleCommon Stock | 5,200 | $3.80 | $19,739.20 |
DisclosureSEC source: 0001376339-23-000018 · wf-form4_168315278769141.xml · nonDerivative · entry 1 Phelan William Lawrence · CIK 0001811814 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,814 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $3.790 to $3.805, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 23:25 UTC |
Phelan William LawrenceChief Accounting Officer
|
SaleCommon Stock | 1,628 | $3.74 | $6,095.23 |
DisclosureSEC source: 0001628280-23-013698 · wf-form4_168263789367161.xml · nonDerivative · entry 1 Phelan William Lawrence · CIK 0001811814 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,014 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 23:24 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 5,987 | $3.74 | $22,415.33 |
DisclosureSEC source: 0001628280-23-013697 · wf-form4_168263786872653.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,400 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 23:23 UTC |
Hulse William Frank IVGeneral Counsel and CAO
|
SaleCommon Stock | 5,988 | $3.74 | $22,419.07 |
DisclosureSEC source: 0001796044-23-000006 · wf-form4_168263777428764.xml · nonDerivative · entry 1 Hulse William Frank IV · CIK 0001796044 · General Counsel and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,434 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 23:21 UTC |
Carlson Peter MChief Financial Officer
|
SaleCommon Stock | 6,094 | $3.74 | $22,815.94 |
DisclosureSEC source: 0001379320-23-000006 · wf-form4_168263769899412.xml · nonDerivative · entry 1 Carlson Peter M · CIK 0001379320 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,411 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:52 UTC |
Phelan William LawrenceChief Accounting Officer
|
SaleCommon Stock | 1,632 | $3.31 | $5,401.92 |
DisclosureSEC source: 0001628280-23-011534 · wf-form4_168142272664297.xml · nonDerivative · entry 1 Phelan William Lawrence · CIK 0001811814 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,642 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:50 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 5,996 | $3.31 | $19,846.76 |
DisclosureSEC source: 0001628280-23-011533 · wf-form4_168142263442757.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,387 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:39 UTC |
Hulse William Frank IVGeneral Counsel and CAO
|
SaleCommon Stock | 5,995 | $3.31 | $19,843.45 |
DisclosureSEC source: 0001796044-23-000005 · wf-form4_168142193153985.xml · nonDerivative · entry 1 Hulse William Frank IV · CIK 0001796044 · General Counsel and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,422 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:37 UTC |
Carlson Peter MChief Financial Officer
|
SaleCommon Stock | 6,100 | $3.31 | $20,191.00 |
DisclosureSEC source: 0001379320-23-000005 · wf-form4_168142185706673.xml · nonDerivative · entry 1 Carlson Peter M · CIK 0001379320 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,505 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:26 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
GrantCommon Stock | 135,065 | $4.62 | $624,000.30 |
DisclosureSEC source: 0001376339-23-000007 · wf-form4_167891919545041.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,383 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:21 UTC |
Carlson Peter MChief Financial Officer
|
GrantCommon Stock | 140,455 | $4.62 | $648,902.10 |
DisclosureSEC source: 0001379320-23-000004 · wf-form4_167891885113196.xml · nonDerivative · entry 1 Carlson Peter M · CIK 0001379320 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,605 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:19 UTC |
Phelan William LawrenceChief Accounting Officer
|
GrantCommon Stock | 53,030 | $4.62 | $244,998.60 |
DisclosureSEC source: 0001376339-23-000006 · wf-form4_167891873589626.xml · nonDerivative · entry 1 Phelan William Lawrence · CIK 0001811814 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,274 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:16 UTC |
Hulse William Frank IVGeneral Counsel and CAO
|
GrantCommon Stock | 136,364 | $4.62 | $630,001.68 |
DisclosureSEC source: 0001796044-23-000004 · wf-form4_167891857858450.xml · nonDerivative · entry 1 Hulse William Frank IV · CIK 0001796044 · General Counsel and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,417 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:43 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 12,355 | $4.24 | $52,442.03 |
DisclosureSEC source: 0001376339-23-000005 · wf-form4_167840178194084.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,318 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:42 UTC |
Phelan William LawrenceChief Accounting Officer
|
SaleCommon Stock | 3,396 | $4.24 | $14,414.66 |
DisclosureSEC source: 0001376339-23-000004 · wf-form4_167840175468517.xml · nonDerivative · entry 1 Phelan William Lawrence · CIK 0001811814 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,244 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:41 UTC |
Carlson Peter MChief Financial Officer
|
SaleCommon Stock | 12,056 | $4.24 | $51,172.90 |
DisclosureSEC source: 0001379320-23-000003 · wf-form4_167840167243742.xml · nonDerivative · entry 1 Carlson Peter M · CIK 0001379320 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,150 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:40 UTC |
Hulse William Frank IVGeneral Counsel and CAO
|
SaleCommon Stock | 11,308 | $4.24 | $47,997.94 |
DisclosureSEC source: 0001796044-23-000003 · wf-form4_167840161646606.xml · nonDerivative · entry 1 Hulse William Frank IV · CIK 0001796044 · General Counsel and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,053 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 22:41 UTC |
Carlson Peter MChief Financial Officer
|
SaleCommon Stock | 19,000 | $4.50 | $85,416.40 |
DisclosureSEC source: 0001379320-23-000002 · wf-form4_167727845960866.xml · nonDerivative · entry 1 Carlson Peter M · CIK 0001379320 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,206 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $4.490 to $4.505, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 22:36 UTC |
Hulse William Frank IVGeneral Counsel and CAO
|
SaleCommon Stock | 15,555 | $4.53 | $70,476.59 |
DisclosureSEC source: 0001796044-23-000002 · wf-form4_167727817921896.xml · nonDerivative · entry 1 Hulse William Frank IV · CIK 0001796044 · General Counsel and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,361 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $4.520 to $5.535, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Read SEC document |
| February 13, 2023 Filed Mar 15, 2023 22:13 UTC |
Whitlow Ricci SChief Operating Officer
|
GrantCommon Stock | 462,857 | $3.50 | $1,619,999.50 |
DisclosureSEC source: 0001798744-23-000004 · wf-form4_167891840398121.xml · nonDerivative · entry 1 Whitlow Ricci S · CIK 0001798744 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,857 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:34 UTC |
Capper Joseph HChief Executive Officer
|
GrantStock Options · Derivative | 3,600,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001456817-23-000005 · wf-form4_167520448219297.xml · derivative · entry 1 Capper Joseph H · CIK 0001456817 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600,000 Underlying: Common Stock · 3,600,000 shares Expires 2030-02-01 F1 · shares: The options granted to the reporting person shall vest 25% on each anniversary of the grant date, subject to the reporting person's continued employment and the attainment of share price performance goals as specified in the Nonqualified Stock Option Agreement F1 · derivative.exercise_date: The options granted to the reporting person shall vest 25% on each anniversary of the grant date, subject to the reporting person's continued employment and the attainment of share price performance goals as specified in the Nonqualified Stock Option Agreement Read SEC document |
| December 22, 2022 Filed Dec 28, 2022 00:55 UTC |
Carlson Peter MChief Financial Officer
|
SaleCommon Stock | 4,992 | $2.82 | $14,052.98 |
DisclosureSEC source: 0001379320-22-000007 · wf-form4_167218891177832.xml · nonDerivative · entry 1 Carlson Peter M · CIK 0001379320 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,206 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $2.810 to $2.8159, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 19:13 UTC |
Newton ToddDirector · Interim CEO
|
GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001376339-22-000116 · wf-form4_166362917429543.xml · nonDerivative · entry 1 Newton Todd · CIK 0001460878 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,618 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests on the one-year anniversary of the grant date, subject to the terms and conditions described in the Restricted Stock Unit Agreement. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 00:17 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 8,329 | $3.46 | $28,785.02 |
DisclosureSEC source: 0001376339-22-000114 · wf-form4_166320103466747.xml · nonDerivative · entry 2 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,673 Read SEC document |
| September 12, 2022 Filed Sep 15, 2022 00:17 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 19,000 | $3.44 | $65,284.00 |
DisclosureSEC source: 0001376339-22-000114 · wf-form4_166320103466747.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,002 F1 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $3.42 to $3.45, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 22:49 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 8,503 | $4.04 | $34,343.62 |
DisclosureSEC source: 0001376339-22-000110 · wf-form4_166069016592798.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,002 F1 · kind: Reflects sale of shares to cover tax withholding obligation upon vesting of previously-granted award. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 18:30 UTC |
Kashyap RohitPresident, WC & Surgical
|
SaleCommon Stock | 12,343 | $4.21 | $51,939.34 |
DisclosureSEC source: 0001376339-22-000108 · wf-form4_166025703691365.xml · nonDerivative · entry 1 Kashyap Rohit · CIK 0001435655 · President, WC & Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,072 F1 · kind: Reflects sale of shares to cover tax withholding obligation upon vesting of previously-granted award. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 21:43 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 19,500 | $3.62 | $70,590.00 |
DisclosureSEC source: 0001376339-22-000103 · wf-form4_165999497107897.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,505 Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 23:09 UTC |
Stein Robert BenjaminPresident, Regenerative Med.
|
SaleCommon Stock | 14,600 | $3.47 | $50,662.00 |
DisclosureSEC source: 0001376339-22-000095 · wf-form4_165663054650638.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,005 F1 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $3.47 to $3.48, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:36 UTC |
Giuliani Michael JDirector
|
GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001834000-22-000002 · wf-form4_165515978637121.xml · nonDerivative · entry 1 Giuliani Michael J · CIK 0001834000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,770 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 22:45 UTC |
WRIGHT TIMOTHY RDirector · Chief Executive Officer
|
SaleCommon Stock | 112,000 | $3.75 | $420,000.00 |
DisclosureSEC source: 0001288245-22-000004 · wf-form4_165516028485064.xml · nonDerivative · entry 1 WRIGHT TIMOTHY R · CIK 0001288245 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,711,324 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| June 07, 2022 Filed Jun 13, 2022 18:38 UTC |
HAWKINS WILLIAM ADirector
|
GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001376339-22-000092 · wf-form4_165515989823045.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,865 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| June 07, 2022 Filed Jun 13, 2022 18:42 UTC |
Newton ToddDirector
|
GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001376339-22-000093 · wf-form4_165516011895878.xml · nonDerivative · entry 1 Newton Todd · CIK 0001460878 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,618 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| June 07, 2022 Filed Jun 13, 2022 22:41 UTC |
LAURENCIN CATO TDirector
|
GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001444810-22-000004 · wf-form4_165516005258655.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,770 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| June 07, 2022 Filed Jun 13, 2022 22:32 UTC |
GARDNER PHYLLISDirector
|
GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001376339-22-000091 · wf-form4_165515952512983.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,670 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| June 07, 2022 Filed Jun 13, 2022 22:31 UTC |
BIERMAN JAMES LDirector
|
GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001376339-22-000090 · wf-form4_165515945678619.xml · nonDerivative · entry 1 BIERMAN JAMES L · CIK 0001189534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,618 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| June 07, 2022 Filed Jun 13, 2022 22:28 UTC |
BEHRENS M KATHLEENDirector
|
GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001376339-22-000089 · wf-form4_165515928060630.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,618 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| May 09, 2022 Filed May 10, 2022 20:44 UTC |
Graves MarkSVP & Chief Compliance Officer
|
SaleCommon Stock | 3,891 | $3.50 | $13,621.61 |
DisclosureSEC source: 0001803893-22-000004 · wf-form4_165221547043264.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,608 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $3.50 to $3.51, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:47 UTC |
Phelan William LawrenceChief Accounting Officer
|
SaleCommon Stock | 5,750 | $3.81 | $21,907.50 |
DisclosureSEC source: 0001376339-22-000070 · wf-form4_165221564361153.xml · nonDerivative · entry 1 Phelan William Lawrence · CIK 0001811814 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,640 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:33 UTC |
Turner Scott MSVP, Operations & Procurement
|
SaleCommon Stock | 5,260 | $4.00 | $21,045.26 |
DisclosureSEC source: 0001376339-22-000062 · wf-form4_165169631789193.xml · nonDerivative · entry 1 Turner Scott M · CIK 0001761796 · SVP, Operations & Procurement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,643 F1 · kind: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $3.999 to $4.01, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 17:28 UTC |
Turner Scott MSVP, Operations & Procurement
|
GrantCommon Stock | 61,472 | $4.62 | $284,000.64 |
DisclosureSEC source: 0001376339-22-000042 · wf-form4_164979887022093.xml · nonDerivative · entry 1 Turner Scott M · CIK 0001761796 · SVP, Operations & Procurement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,903 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 17:26 UTC |
Kashyap RohitPresident, WC & Surgical
|
GrantCommon Stock | 178,571 | $4.62 | $824,998.02 |
DisclosureSEC source: 0001376339-22-000040 · wf-form4_164979878492176.xml · nonDerivative · entry 1 Kashyap Rohit · CIK 0001435655 · President, WC & Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,415 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:30 UTC |
WRIGHT TIMOTHY RDirector · Chief Executive Officer
|
GrantCommon Stock | 602,679 | $4.62 | $2,784,376.98 |
DisclosureSEC source: 0001376339-22-000045 · wf-form4_164979900285144.xml · nonDerivative · entry 1 WRIGHT TIMOTHY R · CIK 0001288245 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,823,324 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:29 UTC |
Hulse William Frank IVGeneral Counsel and CAO
|
GrantCommon Stock | 178,571 | $4.62 | $824,998.02 |
DisclosureSEC source: 0001376339-22-000044 · wf-form4_164979897149747.xml · nonDerivative · entry 1 Hulse William Frank IV · CIK 0001796044 · General Counsel and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,916 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:29 UTC |
Graves MarkSVP & Chief Compliance Officer
|
GrantCommon Stock | 48,485 | $4.62 | $224,000.70 |
DisclosureSEC source: 0001376339-22-000043 · wf-form4_164979892542693.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,499 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:27 UTC |
Phelan William LawrenceChief Accounting Officer
|
GrantCommon Stock | 53,030 | $4.62 | $244,998.60 |
DisclosureSEC source: 0001376339-22-000041 · wf-form4_164979882503804.xml · nonDerivative · entry 1 Phelan William Lawrence · CIK 0001811814 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,390 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:25 UTC |
Carlson Peter MChief Financial Officer
|
GrantCommon Stock | 187,500 | $4.62 | $866,250.00 |
DisclosureSEC source: 0001376339-22-000039 · wf-form4_164979872433149.xml · nonDerivative · entry 1 Carlson Peter M · CIK 0001379320 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,198 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.